An observational study in Non-Center, Diabetic Macular Edema and Phacoemulsification, sponsored by Ain Shams University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-01.
Sponsored by Ain Shams University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Macular Edema with a site in Egypt — 5 open to participants now, 5 under way, none of them phase 3. Macular Edema · Egypt.
Among the 22 studies in Macular Edema with a site in Egypt, this one is one of 3 that started in 2025, is one of 5 observational ones, and was the 19th registered.
759 studies on the registry are indexed under Macular Edema; 66 are open to participants now.
Browse Macular Edema studies →5 of the 22 studies in Macular Edema with a site in Egypt are open now. Recruiting first, the newest first:
Khadija Ahmed Mhrose Glal · Sites in Egypt
Ages 19–69
The General Authority for Teaching Hospitals and Institutes · Sites in Egypt
Ages 18+
Sohag University · Sites in Egypt
Ages 35–65
Tanta University · Sites in Egypt
Healthy volunteers
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 2 · Phase 4 6
First in 2010; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 71 across 127 observational studies indexed under Macular Edema.
Median enrollment 50 across the 17 interventional studies, 52 across the 5 observational. Of the 12 that completed or were terminated, 1 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 22 have an industry lead sponsor. The 10 most frequent:
Ain Shams University is the lead sponsor of 1,958 studies on the registry; 432 are open to participants now.
Of its 35 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Ain Shams University has 2 studies filed under Macular Edema — fewer than ten, so there is no comparison to draw.
1 of the studies in Macular Edema with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07917338Khadija Ahmed Mhrose GlalOral N-Acetylcysteine on Diabetic Macular Edema | 2027-10-01 |
Add it to your calendar (.ics) → With an account.
Among the 22 studies in Macular Edema with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the progression of non-center-involving diabetic macular edema in the early postoperative period following phacoemulsification.
Diabetic patients have been reported to have a higher prevalence of cataract and develop it at an earlier age compared with nondiabetic individuals.
According to recent population-based studies, diabetic macular edema (DME) is the most common cause of vision loss, with the incidence of non-center-involving DME (NCIDME) being higher than that of center-involving DME (CIDME). The prevalence of NCIDME in an urban south Indian population is 10.8%.
This prospective study will be conducted on 50 diabetic patients aged ≥18 years, both sexes, with Grade I - Grade II nuclear cataract and non-center-involving diabetic macular edema (NCIDME).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with Grade I - Grade II nuclear cataract and non-center-involving diabetic macular edema (NCIDME)
Other: Coloured photography · Other: Fluorescein angiography · Other: Optical coherence tomography
Coloured photography will be performed preoperatively and at 3 and 6 months postoperatively.
Fluorescein angiography will be performed preoperatively and at 3 and 6 months postoperatively. The following features will be recorded on each angiography:
Optical coherence tomography (OCT) scanning will be performed using the optical coherence tomography scanner OCT (OPTOVUE OCT). OCT will be performed preoperatively and at 3 and 6 months postoperatively.
Best Corrected Visual Acuity
Best Corrected Visual Acuity (BCVA) will be recorded.
Time frame: 6 months post-procedure
Intra ocular pressure
Intra ocular pressure (IOP) will be recorded.
Time frame: 6 months post-procedure
Central macular thickness (CMT)
Central macular thickness (CMT) will be recorded.
Time frame: 6 months post-procedure
Frequency distribution of Fluorescein leakage
Frequency distribution of Fluorescein leakage will be recorded.
Time frame: 6 months post-procedure
Plan to share: Yes — The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Supporting information: Study protocol
Time frame: After the end of study for one year.
Access criteria: The data will be available upon a reasonable request from the corresponding author.
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Dec 2025, 5 months after the start.
Of 44 observational studies under Macular Edema, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 52. This study's planned 5 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.